IN THE CLAIMS:

Amend claims 1 - 4, 10 - 18, and 26 - 32 to read as follows:

1) (Amended) An anti-allergic pharmaceutical composition containing at least two active agents chosen among : (i) one allergen, (ii) one antihistamine compound, (iii) one inhibitor of histamine synthesis, said active agents being associated in said composition with a pharmaceutically acceptable vehicle.

2) (Amended) The anti-allergic pharmaceutical composition according to claim 1, containing (i) at least one allergen and (ii) at least one antihistamine compound, and optionally (iii) at least one inhibitor of histamine synthesis, in a pharmaceutically acceptable vehicle.

3) (Amended) The anti-allergic pharmaceutical composition according to any of claims 1 or 2, wherein said composition contains (i) at least one allergen and (ii) at least one antihistamine compound, in a pharmaceutically acceptable vehicle, enabling release of the peptides and other chemical substances in independent manner at galenic level.

4) (Amended) A pharmaceutical composition according to any of claims 1 to 3, wherein the allergen is chosen from among the major antigens or mixture of major antigens of acarids able to induce an immune reaction.

10) (Amended) The pharmaceutical composition according to any of claims 1 - 4, wherein the antihistamine compound is chosen from the group comprising: brompheniramine, cetirizine, fexofenadine, cyproheptadine, dexchlorpheniramine, hydroxizine, ketotifene, loratidine, mequitazine, oxotomide, mizolastine, ebastine, astemizole, carbinoxamide, alimemazine, buclizine, cyclizine hydrochlorate, doxylamine.

11) (Amended) The anti-allergic pharmaceutical composition according to any of claims 1 or 2, wherein said composition contains at least one antihistamine compound and at least one inhibitor of histamine synthesis, said compound being associated in said composition with a pharmaceutically acceptable vehicle.

12) (Amended) The pharmaceutical composition according to claim 11, wherein the inhibitor of histamine synthesis is an inhibitor of histidine decarboxylase.

13) (Amended) The pharmaceutical composition according to claim 12, wherein the inhibitor of histidine decarboxylase is tritoqualine.

14) (Amended) The pharmaceutical composition according to any of claims 1 - 4 and 10, wherein said composition contains a quantity of allergen of the order of 1 to 1500 µg.

15) (Amended) The pharmaceutical composition according to any of claims 1 - 4 and 10 - 14, wherein said composition contains a quantity of antihistamine compound of the order of 1 to 2000 mg.

16) (Amended) The pharmaceutical composition according to any of claims 1 - 4 and 10 - 15, wherein said composition contains an inhibitor of histamine synthesis.

17) (Amended) The pharmaceutical composition according to claim 16, wherein said composition contains a quantity of antihistamine compound of between 1 and 2000 mg.

18) (Amended) The pharmaceutical composition according to any of claims 11 to 13, wherein said composition contains from 5 to 200 mg of an antihistamine compound and from 10 to 300 mg of an inhibitor of histidine decarboxylase.

26) (Amended) The pharmaceutical composition according to any of claims 1 - 4 and 10 - 18, wherein said composition permits the TH2/TH1 switch and reduction of the allergic reaction both on the upstream phase (IgE synthesis) and on the downstream phase (synthesis and release of histamine).

27) (Amended) The pharmaceutical composition according to any of claims 1 - 4, 10 - 18 and 26 wherein said composition is released in the form of a transcutaneous patch to allow better access of the allergens used and/or their epitopes to the antigen-presenting cells.

28) (Amended) The pharmaceutical composition according to any of claims 1 - 4, 10 - 18, 26 and 27, wherein said composition is released in mucosal, eye lotion, nasal spray or bronchial form.

29) (Amended) The pharmaceutical composition according to any of claims 1 - 4, 10 - 18 and 26 - 28, wherein said composition is released in a galenical form with programmed mucosal or sublingual and secondarily *per os* disintegration.

30) (Amended) The pharmaceutical composition according to any of claims 1 - 4, 10 - 18 and 26 - 29 for the preparation of a medicinal product intended to treat or prevent allergic hypersensitive reactions.

31) (Amended) The pharmaceutical composition according to any of claims 1 - 4, 10 - 18 and 26 - 30 for the preparation of a medicinal product intended to treat or prevent allergic asthma, allergic rhinitis, atopic and allergic eczema.

32) (Amended) The pharmaceutical composition according to any of claims 1 - 4, 10 - 18 and 26 - 31 for the preparation of a medicinal product intended to treat or prevent allergic symptoms in children, infants and adults.

Add the following new claims: